Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 3 hours ago
Lilly, Boehringer to slash at least $1B each from planned investments in Germany
about 3 hours ago
In response to a planned healthcare reform initiative in Germany that would...
Managing complexity across biopharma modalities
about 3 hours ago
SK pharmteco CEO Joerg Ahlgrimm discusses complexity, global pressure and drug development...
Unlocking Unstructured Data with AI for Optimized Protocol Development
about 5 hours ago
In this podcast, Mike Eckrote, SVP, Strategic Solutions at Advarra, talks about...
Fierce Biotech Fundraising Tracker '26: NewLimit nabs $435M; Accro accrues $50M series C
about 9 hours ago
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million...
Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact
about 9 hours ago
Regeneron has expanded its research alliance with CytomX Therapeutics, paying $37 million...
Mesutoclax points to possible shift in high-risk MDS and AML
about 9 hours ago
Early ASCO 2026 data show strong responses and improved safety with mesutoclax...
As Akeso takes center stage at ASCO, China biotech industry cements its coming of age
about 10 hours ago
In 2017, a little-known company called Nanjing Legend Biotech walked into the...
IMU Biosciences nabs $53M funding round to ‘decode’ the immune system
about 11 hours ago
British medtech startup IMU Biosciences has landed a £40 million ($53 million)...
Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases
about 12 hours ago
Ascidian Therapeutics and Eli Lilly have signed a research collaboration potentially worth...
Foundation Medicine tallies FDA nod to pair its blood test with Pfizer’s prostate cancer combo
1 day ago
Foundation Medicine tallied another nod from the FDA for one of its...
New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells
1 day ago
Anti-aging startup NewLimit is back with a fresh fundraise of $435 million...
ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
1 day ago
To Roche, a phase 3 flop in first-line breast cancer does not...